Literature DB >> 28242659

Molecular Confirmation of the Relationship between Candida guilliermondii Fks1p Naturally Occurring Amino Acid Substitutions and Its Intrinsic Reduced Echinocandin Susceptibility.

Catiana Dudiuk1,2, Daiana Macedo1, Florencia Leonardelli1,2, Laura Theill1, Matias S Cabeza1,2, Soledad Gamarra1, Guillermo Garcia-Effron3,2.   

Abstract

Candida guilliermondii shows intrinsic reduced echinocandin susceptibility. It harbors two polymorphisms (L633M and T634A) in the Fks1p hot spot 1 region. Our objective was to confirm that the reduced echinocandin susceptibility of C. guilliermondii is due to those naturally occurring substitutions. We constructed a Saccharomyces cerevisiae mutant in which a region of the FKS1 gene (including hot spot 1) was replaced with that from C. guilliermondii The chimeric mutants showed 32-fold increases in echinocandin MIC values, confirming the hypothesis.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  Candida guilliermondii; FKS mutations; echinocandin resistance; molecular mechanism

Mesh：

Substances：

Year:  2017        PMID： 28242659      PMCID： PMC5404515          DOI： 10.1128/AAC.02644-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

1.  Candida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program.

Authors:  M A Pfaller; D J Diekema; M Mendez; C Kibbler; P Erzsebet; S-C Chang; D L Gibbs; V A Newell
Journal:  J Clin Microbiol       Date:  2006-10       Impact factor: 5.948

2.  Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp.

Authors:  M A Pfaller; L Boyken; R J Hollis; J Kroeger; S A Messer; S Tendolkar; R N Jones; J Turnidge; D J Diekema
Journal:  J Clin Microbiol       Date:  2009-11-18       Impact factor: 5.948

3.  In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance.

Authors:  M A Pfaller; L Boyken; R J Hollis; J Kroeger; S A Messer; S Tendolkar; D J Diekema
Journal:  J Clin Microbiol       Date:  2007-11-21       Impact factor: 5.948

4.  A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility.

Authors:  Guillermo Garcia-Effron; Santosh K Katiyar; Steven Park; Thomas D Edlind; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2008-04-28       Impact factor: 5.191

5.  Anidulafungin versus fluconazole for invasive candidiasis.

Authors:  Annette C Reboli; Coleman Rotstein; Peter G Pappas; Stanley W Chapman; Daniel H Kett; Deepali Kumar; Robert Betts; Michele Wible; Beth P Goldstein; Jennifer Schranz; David S Krause; Thomas J Walsh
Journal:  N Engl J Med       Date:  2007-06-14       Impact factor: 91.245

6.  Echinocandin Resistance in Candida.

Authors:  David S Perlin
Journal:  Clin Infect Dis       Date:  2015-12-01       Impact factor: 9.079

7.  Studies on the transformation of intact yeast cells by the LiAc/SS-DNA/PEG procedure.

Authors:  R D Gietz; R H Schiestl; A R Willems; R A Woods
Journal:  Yeast       Date:  1995-04-15       Impact factor: 3.239

8.  The Saccharomyces cerevisiae FKS1 (ETG1) gene encodes an integral membrane protein which is a subunit of 1,3-beta-D-glucan synthase.

Authors:  C M Douglas; F Foor; J A Marrinan; N Morin; J B Nielsen; A M Dahl; P Mazur; W Baginsky; W Li; M el-Sherbeini
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

9.  Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome.

Authors:  Annette C Reboli; Andrew F Shorr; Coleman Rotstein; Peter G Pappas; Daniel H Kett; Haran T Schlamm; Arlene L Reisman; Pinaki Biswas; Thomas J Walsh
Journal:  BMC Infect Dis       Date:  2011-09-30       Impact factor: 3.090

10.  Evaluation of an early step-down strategy from intravenous anidulafungin to oral azole therapy for the treatment of candidemia and other forms of invasive candidiasis: results from an open-label trial.

Authors:  Jose Vazquez; Annette C Reboli; Peter G Pappas; Thomas F Patterson; John Reinhardt; Peter Chin-Hong; Ellis Tobin; Daniel H Kett; Pinaki Biswas; Robert Swanson
Journal:  BMC Infect Dis       Date:  2014-02-21       Impact factor: 3.090
View more
  8 in total

1.  Antifungal Activity of SCY-078 and Standard Antifungal Agents against 178 Clinical Isolates of Resistant and Susceptible Candida Species.

Authors:  Wiley A Schell; A M Jones; Katyna Borroto-Esoda; Barbara D Alexander
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

2.  Sequencing of FKS Hot Spot 1 from Saprochaete capitata To Search for a Relationship to Reduced Echinocandin Susceptibility.

Authors:  Inés Arrieta-Aguirre; Pilar Menéndez-Manjón; María Soledad Cuétara; Iñigo Fernández de Larrinoa; Juan Carlos García-Ruiz; María Dolores Moragues
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

3.  In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European Study.

Authors:  Guillermo Quindós; Katherine Miranda-Cadena; Rosario San-Millán; Katyna Borroto-Esoda; Emilia Cantón; María José Linares-Sicilia; Axel Hamprecht; Isabel Montesinos; Anna Maria Tortorano; Anna Prigitano; Matxalen Vidal-García; Cristina Marcos-Arias; Andrea Guridi; Ferran Sanchez-Reus; Jesús Machuca-Bárcena; Manuel Antonio Rodríguez-Iglesias; Estrella Martín-Mazuelos; Carmen Castro-Méndez; Leyre López-Soria; Alba Ruiz-Gaitán; Marcelo Fernandez-Rivero; Damaris Lorenzo; Javier Capilla; Antonio Rezusta; Javier Pemán; Josep Guarro; Joana Pereira; Célia Pais; Orazio Romeo; Guillermo Ezpeleta; Nerea Jauregizar; David Angulo; Elena Eraso
Journal:  Front Cell Infect Microbiol       Date:  2022-05-16       Impact factor: 6.073

4.  Clinical and Microbiological Characteristics of Candida guilliermondii and Candida fermentati.

Authors:  Tatsuro Hirayama; Taiga Miyazaki; Yuka Yamagishi; Hiroshige Mikamo; Takashi Ueda; Kazuhiko Nakajima; Yoshio Takesue; Yoshitsugu Higashi; Yoshihiro Yamamoto; Muneyoshi Kimura; Hideki Araoka; Shuichi Taniguchi; Yuichi Fukuda; Yumi Matsuo; Akiko Furutani; Kohei Yamashita; Takahiro Takazono; Tomomi Saijo; Shintaro Shimamura; Kazuko Yamamoto; Yoshifumi Imamura; Koichi Izumikawa; Katsunori Yanagihara; Shigeru Kohno; Hiroshi Mukae
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191

Review 5.  Responding to the emergence of antifungal drug resistance: perspectives from the bench and the bedside.

Authors:  Justin Beardsley; Catriona L Halliday; Sharon C-A Chen; Tania C Sorrell
Journal:  Future Microbiol       Date:  2018-08-16       Impact factor: 3.165

Review 6.  Rezafungin-Mechanisms of Action, Susceptibility and Resistance: Similarities and Differences with the Other Echinocandins.

Authors:  Guillermo Garcia-Effron
Journal:  J Fungi (Basel)       Date:  2020-11-01

Review 7.  Pharmacodynamics, Mechanisms of Action and Resistance, and Spectrum of Activity of New Antifungal Agents.

Authors:  Nathan P Wiederhold
Journal:  J Fungi (Basel)       Date:  2022-08-16

Review 8.  Dermatophyte Resistance to Antifungal Drugs: Mechanisms and Prospectus.

Authors:  Nilce M Martinez-Rossi; Tamires A Bitencourt; Nalu T A Peres; Elza A S Lang; Eriston V Gomes; Natalia R Quaresemin; Maíra P Martins; Lucia Lopes; Antonio Rossi
Journal:  Front Microbiol       Date:  2018-05-29       Impact factor: 5.640
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.